Inotropes in Acute Heart Failure: From Guidelines to Practical Use: Therapeutic Options and Clinical Practice
Inotropes are pharmacological agents that are indicated for the treatment of patients presenting with acute heart failure (AHF) with concomitant hypoperfusion due to decreased cardiac output. They are usually administered for a short period during the initial management of AHF until haemodynamic sta...
Guardado en:
Autores principales: | , , , , |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Radcliffe Medical Media
2019
|
Materias: | |
Acceso en línea: | https://doaj.org/article/0e11d0ccd47948c2b9b2449bc12d3d81 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
id |
oai:doaj.org-article:0e11d0ccd47948c2b9b2449bc12d3d81 |
---|---|
record_format |
dspace |
spelling |
oai:doaj.org-article:0e11d0ccd47948c2b9b2449bc12d3d812021-12-04T16:01:59ZInotropes in Acute Heart Failure: From Guidelines to Practical Use: Therapeutic Options and Clinical Practice10.15420/cfr.2019.11.22057-75592057-7540https://doaj.org/article/0e11d0ccd47948c2b9b2449bc12d3d812019-11-01T00:00:00Zhttps://www.cfrjournal.com/articles/Inotropes-in-Acute-Heart-Failurehttps://doaj.org/toc/2057-7540https://doaj.org/toc/2057-7559Inotropes are pharmacological agents that are indicated for the treatment of patients presenting with acute heart failure (AHF) with concomitant hypoperfusion due to decreased cardiac output. They are usually administered for a short period during the initial management of AHF until haemodynamic stabilisation and restoration of peripheral perfusion occur. They can be used for longer periods to support patients as a bridge to a more definite treatment, such as transplant of left ventricular assist devices, or as part of a palliative care regimen. The currently available inotropic agents in clinical practice fall into three main categories: beta-agonists, phosphodiesterase III inhibitors and calcium sensitisers. However, due to the well-documented potential for adverse events and their association with increased long-term mortality, physicians should be aware of the indications and dosing strategies suitable for different types of patients. Novel inotropes that use alternative intracellular pathways are under investigation, in an effort to minimise the drawbacks that conventional inotropes exhibit.Vasiliki BistolaAngelos Arfaras-MelainisEftihia PolyzogopoulouIgnatios IkonomidisJohn ParissisRadcliffe Medical MediaarticleDiseases of the circulatory (Cardiovascular) systemRC666-701ENCardiac Failure Review , Vol 5, Iss 3, Pp 133-139 (2019) |
institution |
DOAJ |
collection |
DOAJ |
language |
EN |
topic |
Diseases of the circulatory (Cardiovascular) system RC666-701 |
spellingShingle |
Diseases of the circulatory (Cardiovascular) system RC666-701 Vasiliki Bistola Angelos Arfaras-Melainis Eftihia Polyzogopoulou Ignatios Ikonomidis John Parissis Inotropes in Acute Heart Failure: From Guidelines to Practical Use: Therapeutic Options and Clinical Practice |
description |
Inotropes are pharmacological agents that are indicated for the treatment of patients presenting with acute heart failure (AHF) with concomitant hypoperfusion due to decreased cardiac output. They are usually administered for a short period during the initial management of AHF until haemodynamic stabilisation and restoration of peripheral perfusion occur. They can be used for longer periods to support patients as a bridge to a more definite treatment, such as transplant of left ventricular assist devices, or as part of a palliative care regimen. The currently available inotropic agents in clinical practice fall into three main categories: beta-agonists, phosphodiesterase III inhibitors and calcium sensitisers. However, due to the well-documented potential for adverse events and their association with increased long-term mortality, physicians should be aware of the indications and dosing strategies suitable for different types of patients. Novel inotropes that use alternative intracellular pathways are under investigation, in an effort to minimise the drawbacks that conventional inotropes exhibit. |
format |
article |
author |
Vasiliki Bistola Angelos Arfaras-Melainis Eftihia Polyzogopoulou Ignatios Ikonomidis John Parissis |
author_facet |
Vasiliki Bistola Angelos Arfaras-Melainis Eftihia Polyzogopoulou Ignatios Ikonomidis John Parissis |
author_sort |
Vasiliki Bistola |
title |
Inotropes in Acute Heart Failure: From Guidelines to Practical Use: Therapeutic Options and Clinical Practice |
title_short |
Inotropes in Acute Heart Failure: From Guidelines to Practical Use: Therapeutic Options and Clinical Practice |
title_full |
Inotropes in Acute Heart Failure: From Guidelines to Practical Use: Therapeutic Options and Clinical Practice |
title_fullStr |
Inotropes in Acute Heart Failure: From Guidelines to Practical Use: Therapeutic Options and Clinical Practice |
title_full_unstemmed |
Inotropes in Acute Heart Failure: From Guidelines to Practical Use: Therapeutic Options and Clinical Practice |
title_sort |
inotropes in acute heart failure: from guidelines to practical use: therapeutic options and clinical practice |
publisher |
Radcliffe Medical Media |
publishDate |
2019 |
url |
https://doaj.org/article/0e11d0ccd47948c2b9b2449bc12d3d81 |
work_keys_str_mv |
AT vasilikibistola inotropesinacuteheartfailurefromguidelinestopracticalusetherapeuticoptionsandclinicalpractice AT angelosarfarasmelainis inotropesinacuteheartfailurefromguidelinestopracticalusetherapeuticoptionsandclinicalpractice AT eftihiapolyzogopoulou inotropesinacuteheartfailurefromguidelinestopracticalusetherapeuticoptionsandclinicalpractice AT ignatiosikonomidis inotropesinacuteheartfailurefromguidelinestopracticalusetherapeuticoptionsandclinicalpractice AT johnparissis inotropesinacuteheartfailurefromguidelinestopracticalusetherapeuticoptionsandclinicalpractice |
_version_ |
1718372718162739200 |